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Jean-Christophe Leroux1 • E. Richard Stanley2 • Michael Detmar1
Received: 26 February 2016 / Accepted: 20 July 2016 / Published online: 27 July 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Lymphatic vessels play important roles in fluid
drainage and in immune responses, as well as in patho-
logical processes including cancer progression and
inflammation. While the molecular regulation of the ear-
liest lymphatic vessel differentiation and development has
been investigated in much detail, less is known about the
control and timing of lymphatic vessel maturation in dif-
ferent organs, which often occurs postnatally. We investi-
gated the time course of lymphatic vessel development on
the pleural side of the diaphragmatic muscle in mice, the
so-called submesothelial initial diaphragmatic lymphatic
plexus. We found that this lymphatic network develops
largely after birth and that it can serve as a reliable and
easily quantifiable model to study physiological lymphan-
giogenesis in vivo. Lymphangiogenic growth in this tissue
was highly dependent on vascular endothelial growth fac-
tor receptor (VEGFR)-3 signaling, whereas VEGFR-1 and
-2 signaling was dispensable. During diaphragm develop-
ment, macrophages appeared first in a linearly arranged
pattern, followed by ingrowth of lymphatic vessels along
these patterned lines. Surprisingly, ablation of macro-
phages in colony-stimulating factor-1 receptor (Csf1r)-
deficient mice and by treatment with a CSF-1R-blocking
antibody did not inhibit the general lymphatic vessel
development in the diaphragm but specifically promoted
branch formation of lymphatic sprouts. In agreement with
these findings, incubation of cultured lymphatic endothelial
cells with conditioned medium from P7 diaphragmatic
macrophages significantly reduced LEC sprouting. These
results indicate that the postnatal diaphragm provides a
suitable model for studies of physiological lymphangio-
genic growth and maturation, and for the identification of
modulators of lymphatic vessel growth.
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Introduction
Lymphatic vessels play important roles in physiological
tissue fluid homeostasis, immune surveillance and dietary
lipid uptake, as well as in a range of pathological condi-
tions including chronic inflammation, wound healing and
cancer progression [15, 37]. Despite these important roles,
only few mediators of lymphatic vessel development and
function have been identified. Among those, vascular
endothelial growth factor receptor (VEGFR)-3 and its
ligands VEGF-C and VEGF-D represent the major lym-
phangiogenic signaling system. VEGFR-2 signaling might
also promote lymphangiogenesis during metastasis forma-
tion in the lymph node [12] and during lymphatic vessel
enlargement in inflamed skin [21, 38], but the role of
VEGFR-2 during developmental lymphangiogenesis is less
clear.
The lymphatic vascular system starts to develop around
midgestation by the budding of Prox-1-positive lymphatic
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endothelial cells (LECs), which also express VEGFR-3,
from the cardinal vein. These cells then migrate toward a
VEGF-C gradient and form a lymphatic vessel plexus,
which becomes remodeled from embryonic day (E) 14.5
on, and matures until postnatal time points [28, 31, 40].
Maturation processes include the differentiation of lym-
phatic vessels into capillaries and collecting lymphatic
vessels that are characterized by sparse smooth muscle cell
coverage, down-regulation of LYVE-1 expression, and
valves that prevent the backflow of lymph [23, 30].
Importantly, the time course of lymphatic vessel develop-
ment can vary in different organs, and for many organs, the
exact time course is still unknown.
There are few in vivo models that allow a quantitative
characterization of physiological lymphangiogenesis. The
two most widely used models study the development of
superficial lymphatic vessels in the tail dermis [39] and the
development of collecting lymphatic vessels in the
mesentery [27]. A potential disadvantage of both models is
that lymphatic vessels in adults cannot be studied with
whole-mount approaches and that the study of lymphatic
vessel sprouting in vivo remains rather difficult.
The role of macrophages in pathological lymphangio-
genesis has been thoroughly investigated (reviewed in
[11]), and macrophages can serve in these settings as
sources of pro-lymphangiogenic growth factors such as
VEGF-C and VEGF-D [3, 18, 19]. In contrast, the role of
macrophages in developmental lymphangiogenesis is less
clear. Macrophage depletion resulted in reduced lymphatic
vessel branching in the ears and the trachea of newborns
[20], whereas it increased the lymphatic vessel diameter in
embryonic skin and led to hypoplastic jugular lymph sacs
[10]. These differing results suggest a tissue-dependent role
of macrophages in developmental lymphangiogenesis.
The aim of the present study was to investigate the
developmental time course of lymphatic vessel formation
on the pleural side of the diaphragm, the so-called sub-
mesothelial initial diaphragmatic lymphatic plexus [26],
and its potential molecular and cellular mediators. We
found that development of the diaphragmatic lymphatic
plexus largely occurs postnatally and that it represents a
sensitive model to study the regulation of lymphangio-
genesis in vivo. Normal development was dependent on
VEGFR-3 signaling but largely independent of VEGFR-1
or VEGFR-2 signaling. Studies in colony-stimulating fac-
tor-1 receptor (Csf1r)-deficient mice and antibody deple-
tion of CSF-1R surprisingly revealed that macrophages are
dispensable for the general development of the diaphrag-
matic lymphatic network but that they restrain the forma-
tion of lymphatic vessel branches by secreted factors.
Materials and methods
In vivo experiments
Mice were bred and housed in the animal facility of ETH
Zurich. Experiments were performed in accordance with
the animal protocol 131/2014 approved by the local vet-
erinary authorities (Kantonales Veterinäramt Zürich).
Prox-1 GFP mice [5] were provided by Dr. Young-Kwon
Hong (Keck School of Medicine, USD, California). K14-
VEGFR-3-Fc mice (Mäkinen et al., 2001) were provided
by Dr. Kari Alitalo (Institute of Biomedicine, Biomedicum,
University of Helsinki). Csf1r-/- mice [6] were obtained
by mating heterozygotes that had been backcrossed for 10
generations to the FVB/NJ background. For the in utero
VEGFR blockade, pregnant C57BL/6 female mice were
injected intraperitoneally (i.p.) with 800 lg blocking anti-
bodies against VEGFR-1 (mF1), VEGFR-2 (DC101) or
VEGFR-3 (mF4-31C1) (kindly provided by Dr. Bronek
Pytowski, ImClone Systems/Eli Lilly), or with control rat
IgG (Sigma-Aldrich) at E16.5 and E18.5, and pups were
killed at postnatal day (P) 5. To deplete macrophages with
an antibody-mediated approach, pups were injected (i.p.)
with the purified neutralizing rat anti-mouse CSF-1R
monoclonal antibody AFS98 [36] or rat IgG (Sigma)
(36.5–50 mg/kg bodyweight) at P0, P1, P3 and P5 and then
killed at P7.
Immunostaining
Tail skin and diaphragms were fixed in fresh 4 %
paraformaldehyde (PFA) for 2 h and blocked at room
temperature for 3 h in phosphate-buffered saline (PBS)
containing 5 % donkey serum, 1 % bovine serum albumin
(BSA) and 0.1 % Triton-X. The following antibodies were
incubated overnight: Rabbit anti-LYVE-1 (AngioBio), goat
anti-LYVE-1 (R&D Systems), rat anti-CD31 (BD Bio-
sciences Pharmingen), goat anti-CD206 (R&D Systems),
mouse anti-smooth muscle actin (Sigma-Aldrich), rat anti-
CD68 (Abcam), goat anti-Prox-1 (R&D Systems), rabbit
anti-Prox-1 (kind gift of Dr. Kari Alitalo), rat anti-F4/80
(Abcam) and rat anti-CSF-1R (AFS98 hybridoma anti-
body). After an intense washing step, tissues were incu-
bated for 2 h at room temperature with Alexa Fluor 488,
594 or 647 nm-conjugated secondary antibodies (Invitro-
gen) and mounted in Vectashield (Vector) for confocal
imaging. Whole-mount z-stack images were acquired with
a LSM 710 FCS confocal microscope and ZEN software
(Zeiss) and processed with Photoshop CS5 (Adobe) and
ImageJ software (NIH).
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Morphological analyses of diaphragmatic lymphatic
vessels
To analyze the lymphatic vessels on the pleural side of the
diaphragmatic muscle, a diaphragm segment was imaged
by taking partially overlapping confocal images (using a
109 0.3NA EC Plan-Neofluar objective) from the thorax
wall to the central tendon in the crural diaphragm region.
Pictures were merged using Photoshop software, and the
merged diaphragm segments were analyzed with ImageJ to
quantify branch numbers, average branch length and rela-
tive LYVE-1-positive area. The diameter was calculated by
dividing the LYVE-1? area by the total vessel length.
Lymphatic vessels on the central tendon were excluded
from the analyses. Photoshop was used to count lymphatic
vessel loops.
Hybridoma cell culture and anti-CSF-1R (AFS98)
antibody purification
The AFS98 hybridoma cell line was a kind gift from Dr.
Shin-Ichi Nishikawa, RIKEN Center for Developmental
Biology, Kobe, Japan. AFS98 cells were cultured at 37 C
with 5 % CO2 in serum-free Hybridoma-SFM medium
(Gibco, Life Technologies). The anti-CSF-1R antibody was
purified from pooled medium with a Profinia Protein
Purification device (Bio-Rad), using a protein G column
(GE Healthcare Life Sciences) and treated with an endo-
toxin removing gel (Detoxi-Gel, Thermo Scientific) to
remove possible endotoxin contamination.
Lymphatic sprouting assay
Macrophage-conditioned medium was obtained by isolat-
ing CD11b? cells from diaphragms of P7 WT pups
(n = 6) by MACS (Miltenyi Biotech), and culturing them
in 24 wells for 48 h in RPMI ? 1 % FBS medium.
Sprouting assays were performed largely as described [32].
Gelatin-covered cytodex microcarrier beads (Sigma) were
coated with lymphatic endothelial cells at a 1:40 bead-to-
cell ratio and incubated at 37 C. LEC-covered beads were
labeled with Cell Tracker Green (CTG, Invitrogen) and
embedded into a 1 mg/mL type I collagen solution (Ad-
vanced Biomatrix) in black 96-well clear-bottom plates
(Costar). The collagen was left to polymerize before
incubation with a medium consisting of a 1:1 mixture of
EBM ? 20 % FBS and macrophage-conditioned medium
or RPMI ? 1 % FBS medium, with or without the addition
of 80 ng/ml recombinant human VEGF-A165 (R&D Sys-
tems) and 80 ng/ml bFGF (R&D Systems). Samples were
fixed in 2 % paraformaldehyde (Sigma). The sprouts were
imaged with an automated epifluorescence microscope
ImageXpress micro (Molecular Devices, California, USA),
equipped with a 4 9 0.2 NA Plan Apo objective (Nikon,
Tokyo, Japan), a Lumencor Spectra X light engine (Lu-
mencor, Oregon, USA), a Photometrics CoolSNAP HQ
digital CCD camera (Photometrics, Arizona, USA) and a
488-nM excitation FITC filter set and controlled with the
MetaXpress 5 software (Molecular Devices). The number
of sprouts per bead was analyzed manually per 96-well
image.
Preparation and characterization of PEGylated
fluorescent beads
Yellow–green fluorescent polystyrene amine-modified
microspheres (FluoSpheres, Molecular Probes Europe BV,
Netherlands) of 1 lm diameter (2 mg, 12 nmol) were
washed with water twice by centrifugation and then
resuspended in 1 ml of DMSO and sonicated for 10 min in
a bath sonicator. Methoxy-PEG 5000-NHS (JenKem
Technology, Allen, TX, USA) (1 mg, 200 nmol) was
added, and the mixture was left to react overnight at room
temperature under stirring. After reaction, the mixture was
diluted in 5 ml of water and centrifuged (40009g, 15 min,
15 C) to remove the DMSO. The particles were washed 4
times by centrifugation/resuspension in water to remove
the excess of unreacted polymer. Finally, they were
resuspended in 1 ml of PBS, resulting in a final concen-
tration of 2 mg/ml. The microspheres were characterized in
terms of f-potential by laser Doppler anemometry using a
DelsaNano C Particle Analyzer (Beckman Coulter, Kre-
feld, Germany). The f-potential value of -1 mV indicated
adequate PEGylation of the beads.
Lymphatic drainage assay
To determine the lymphatic drainage of peritoneal fluid
into the draining lymph nodes via diaphragmatic lymphatic
vessels, P7 pups were injected i.p. with 10 ll of 0.2 mg/ml
PEGylated 1-lm-diameter yellow–green fluorescent
microspheres in PBS. At 1 h after injection, beads were
visualized in situ within draining lymph nodes using a
Zeiss StereoLumar.V12 stereomicroscope (Carl Zeiss,
Oberkochen, Germany) equipped with an EMCCD camera
(Evolve eXcelon, Photometrics, Tucson, AZ), a high-
powered light-emitting diode (LED) system with illumi-
nation at 470 nm (CoolLED, Andover, UK) and specific
filters for FITC (Zeiss). For FACS analysis, after 1 h, the
draining mediastinal lymph nodes were collected and
passed through a 40-lm cell strainer (Invitrogen) to gen-
erate single-cell suspensions. FACS analyses were per-
formed using a FACSAria and the FACSDiva software
(BD Biosciences), and beads per lymph nodes were
determined. Pictures were taken with a Zeiss StereoLu-
mar.V12 stereomicroscope.
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Statistical analyses
Data are shown as mean ± SD, and two-tailed Student’s
t test or one-way ANOVA and the Dunnett’s multiple
comparison tests were used to compare two or more
groups, respectively. Statistical significance is indicated by
asterisks: *p\ 0.05, **p\ 0.01, ***p\ 0.001. Statistical
significance was set as p\ 0.05.
Results
Lymphatic vessels on the pleural side
of the diaphragmatic muscle develop and mature
postnatally
To investigate whether the submesothelial initial diaphrag-
matic lymphatic plexus might be suitable as a reliable and
quantifiable model of developmental lymphangiogenesis,
we first stained diaphragm whole mounts from newborn
C57BL/6 mice for the lymphatic vessel markers LYVE-1
(Fig. 1a, d) and Prox-1 (Fig. 1b), as well as for the pan-
endothelial marker CD31 (Fig. 1e). LYVE-1? vessels also
expressed Prox-1 (Fig. 1c) and CD31 (Fig. 1f), allowing the
visualization of individual lymphatic vessels and branches, a
feature required for the detailed analysis and quantification
of lymphatic vessel growth.
We next studied the lymphangiogenic processes on the
pleural side of the diaphragmatic muscle by analysis of
whole mounts at time points E16.5, E18.5, P0, P5 and P7.
Wide-field images showed that only very few LYVE-1?
lymphatic vessels were present close to the thorax wall at
E16.5, with slightly more vessels apparent at E18.5
(Fig. 1g). At P0, the lymphatic vessels grew radially from
the thorax wall toward the central tendon. At P5, the radial
growth of lymphatic vessels was more pronounced, and at
P7, a fully developed lymphatic vessel network was visible
with lymphatic vessels spanning from the thorax wall to the
central tendon as individual or branched vessels (Fig. 1g).
At E16.5 and E18.5, LYVE-1 was also expressed in liver
tissue that was attached to the diaphragm at those time
points (Fig. 1g, marked by $). For further high-resolution
confocal imaging and quantification, lateral segments of
the pleural diaphragmatic muscle were chosen as indicated
in Fig. 1g. Confocal images of lateral segments stained for
LYVE-1 showed the expansion of the lymphatic vessel
network from P0 to P5 and P7 in more detail (Fig. 1h) and
also allowed the visualization of lymphatic vessels on the
pleural side of the diaphragm at 6 weeks of age (Fig. 1h).
High-magnification images revealed lymphatic vessel
sprouts at P7 (Fig. 1i, arrows). At 4 weeks of age, the
lymphatic vessels showed characteristics of maturation
such as smooth muscle cell coverage and the presence of
valves (Fig. 1j; arrow). To investigate whether LYVE-1
might be downregulated on mature lymphatic vessels at
later time points, diaphragm whole mounts of 6-week-old
Prox-1 GFP transgenic mice (Fig. 1k) were stained for
CD31 (red, Fig. 1l) and LYVE-1 (cyan, Fig. 1m). We
found that LYVE-1 expression on the Prox-1 and CD31-
positive lymphatic vessels located close to the thorax wall
was weaker than at earlier time points (Fig. 1n), demon-
strating that the lymphatic vessels on the pleural side of the
diaphragmatic muscle also partially show this maturation
phenotype.
Diaphragmatic lymphatic vessel growth is VEGFR-3
dependent
We next investigated the role of VEGFR-3 in the devel-
opment of lymphatic vessels on the pleural side of the
diaphragm. Diaphragm whole mounts obtained from K14-
VEGFR-3-Fc transgenic mice and wild-type (WT) litter-
mates were stained for LYVE-1 at P7. K14-VEGFR-3-Fc
transgenic mice express a soluble form of VEGFR-3 con-
stitutively, which acts as a decoy receptor for its ligands
VEGF-C and VEGF-D, under control of the K14 promoter.
Merged confocal images of the diaphragm segments
revealed an almost complete absence of lymphatic vessels
in the diaphragms of K14-VEGFR-3-Fc mice (Fig. 2a, b).
To further quantify this phenotype, we measured the
LYVE-1? area, the average lymphatic branch length and
the average lymphatic vessel diameter. K14-VEGFR-3-Fc
mice had a significant, 92 % decrease in the LYVE-1?
area (WT: 0.12 ± 0.036 mm2, TG: 0.01 ± 0.2 mm2,
n = 5–6 per group; p = 0.00086, Fig. 2c), and a 92 %
decrease in branch numbers (WT: 39.4 ± 11.28, TG:
3 ± 6, n = 5–6 per group; p = 0.00067, Fig. 2d) com-
pared to WT controls. In the few cases (2 out of 6 K14-
VEGFR-3-Fc pups) where a few lymphatic vessels were
detectable, the average branch length and diameter
remained unchanged compared to WT controls (Fig. 2e, f).
Since both VEGFR-2 and VEGFR-3 have been impli-
cated in physiological and pathological lymphatic vessel
formation [9, 13, 38, 41], we next aimed to dissect the
individual influence of different VEGFRs during lymphatic
development in the diaphragm. Pregnant C57BL/6 female
mice were injected i.p. with blocking antibodies against
VEGFR-1 (mF1), VEGFR-2 (DC101) or VEGFR-3 (mF4),
or IgG control at E16.5 and E18.5, when the diaphragmatic
lymphatic plexus in the embryos is just about to form, and
analyses of diaphragmatic lymphatic vessels were per-
formed at P5. Confocal images of LYVE-1-stained dia-
phragm segments revealed an almost complete inhibition
of lymphatic vessel growth in diaphragms of mF4-treated
pups, as compared to IgG controls (Fig. 2g, j). In contrast,
treatment with mF1 or DC101 did not lead to any obvious
516 Angiogenesis (2016) 19:513–524
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alterations of the lymphatic vessel phenotype on the pleural
side of the diaphragmatic muscle (Fig. 2g–j). Quantitative
analyses revealed that systemic blockade of VEGFR-3
significantly reduced the LYVE-1? area by 75 % (IgG:
0.167 ± 0.065 mm2, mF4: 0.041 ± 0.043 mm2, n = 5–9
pups per group; p B 0.01, Fig. 2k) and the branch numbers
by 81 % (IgG: 38.3 ± 7.8, mF4: 7.2 ± 5, n = 5–9 pups
per group; p B 0.001, Fig. 2l) compared to IgG controls.
With blockade of VEGFR-2, there was a nonsignificant
trend toward reduced LYVE-1? area and branch counts,
whereas blockade of VEGFR-1 had no discernable impact
on these parameters (Fig. 2k–n). The average length of
lymphatic vessel branches and the average lymphatic ves-
sel diameter were comparable in all groups.
Fig. 1 Lymphatic vessels on the pleural side of the diaphragmatic
muscle develop and mature postnatally. Whole mounts of C57BL/6
mice show that on the pleural side of the diaphragmatic muscle,
LYVE-1-positive vessel structures (green) co-stain for Prox-1 (red) at
P7 (a–c) and for CD31 (red) at P5 (d–f). Wide-field images of LYVE-
1 whole mounts demonstrate few LYVE-1-positive vessel structures
at E16.5 and E18.5 and an expansion of the vessel network from P0 to
P7 (g). $ mark unspecific staining of liver tissue. Dotted lines mark
the area of the diaphragm that is used for whole-mount imaging and
quantifications (g). Merged confocal images of lateral diaphragm
segments stained for LYVE-1 show the expansion of the vessel plexus
starting from P0 to 6 W (h). Stars mark the central tendon region.
High-magnification confocal images allow the visualization of
diaphragmatic lymphatic vessel sprouts at P7 (i arrows). Prox-1
(cyan), a-SMA (red) and CD31 (green) whole-mount stainings show
valves (arrows) and SMC coverage of lymphatic vessels, located
close to the thorax wall (j). CD31 (red) and LYVE-1 (cyan)
diaphragm whole mounts of a 6-week-old Prox-1 GFP mouse show
LYVE-1 down-regulation on diaphragmatic lymphatic vessels located
close to the thorax wall (K-N). Scale bars a–f 100 lm, g and h 1 mm,
i 50 lm, j 100 lm, k–n 50 lm. (Color figure online)
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VEGFR-3 blockade leads to similar lymphatic vessel
phenotypes in the tail dermis and on the pleural
diaphragm side
To investigate whether similar changes as in the diaphragm
model could be seen in another model for developmental
lymphangiogenesis, we studied the superficial lymphatic
vessel plexus in the tail dermis. Confocal images of LYVE-
1 whole mounts of the tail dermis of K14-VEGFR-3-Fc
transgenic mice and WT littermates showed that the
transgene expression almost completely inhibited the
development of the superficial lymphatic plexus at P7
(Fig. 3a, b). LYVE-1 whole mounts of tail dermis after in
utero treatment with IgG or with VEGFR-1 (mF1),
VEGFR-2 (DC101) or VEGFR-3 (mF4)-blocking anti-
bodies revealed that only blockade of VEGFR-3 inhibited
lymphangiogenesis at P5 (Fig. 3c–f), similar to the findings
in the diaphragm.
Macrophages are closely aligned with lymphatic
vessels and their sprouting tips, and emerge
before lymphatic vessels
Macrophages have been reported to share an intimate
association with lymphatic vessels [10, 42] and to drive
lymphangiogenesis in many tumor and inflammation set-
tings [11]. To investigate whether macrophages are also
important for the normal lymphatic vessel development in
the diaphragm, we first investigated the localization of
macrophages and lymphatic vessels. By whole-mount
staining, we detected an alignment of F4/80 (green)- and
CD206 (cyan)-positive macrophages with LYVE-1 (red)-
Fig. 2 Diaphragmatic lymphatic vessel growth is VEGFR-3 depen-
dent. Segments of diaphragm whole mounts stained for LYVE-1 of
P7 WT (a) and K14-VEGFR-3-Fc transgenic (TG) littermates (b).
Quantification of diaphragmatic lymphatic vessel (LV) development
of WT and K14-VEGFR-3-Fc transgenic (TG) pups (c–f). Dots
represent mean values per mouse, and lines indicate the group means.
As only 2 out of 6 diaphragm segments of TG pups had
detectable vessels, no statistical analysis was performed for the
parameters average LV branch length (e) and LV diameter (f).
Segments of LYVE-1-stained pleural diaphragm whole mounts of P5
pups treated with IgG control (g) or antibodies blocking VEGFR-1
(mF1) (h), VEGFR-2 (DC101) (i) or VEGFR-3 (mF4) (j) in utero at
E16.5 and E18.5. Quantification of diaphragmatic lymphatic vessel
development of VEGFR-blocking antibody-treated pups (k–n). Dots
represent mean values per mouse, and lines indicate the group means.
Scale bars 1 mm. *p\ 0.05; **p\ 0.01; ***p\ 0.001
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positive growing lymphatic vessels on the pleural side of
the diaphragmatic muscle at P7 (Fig. 4a). Intriguingly,
high-magnification confocal images showed a close inter-
action of sprouting lymphatic vessels (LYVE-1 green,
Prox-1 red) and macrophages (cyan) at P8 (Fig. 4b, c). We
did not observe Prox-1-positive macrophages in the dia-
phragm, suggesting that macrophages do not acquire a
lymphatic endothelial cell signature during diaphragm
development (Fig. 4c). LYVE-1- and CD206-positive
macrophages were already present in E14.5 diaphragms
when CD31- and LYVE-1-positive vessel structures were
not yet detectable (Fig. 4d). Again, also at this time point,
the few Prox-1-positive LECs (cyan) that were
detectable did not co-stain for CD68 (green, Fig. 4e).
Colony-stimulating factor-1 receptor-positive
macrophages negatively regulate lymphatic vessel
branching on the pleural side of the diaphragm
To investigate the biological role of macrophages during
lymphatic vessel development in the diaphragm, we next
studied the lymphangiogenic process after systemic inhibi-
tion of CSF-1R signaling. CSF-1R signaling regulates tissue
macrophage homeostasis, and its absence leads to macro-
phage depletion [4, 6]. We found that CSF-1R (red) was
expressed by LYVE-1? macrophages but not by lymphatic
vessels at P6 (Fig. 5a). The effects of macrophage depletion
were assessed by immunofluorescent stainings of dia-
phragms, tail skin and back skin for the macrophage markers
F4/80, CD68, CD11b, CD206, and for LYVE-1 (Fig. 5b, c,
f, g and Supplementary Material S1A–D, M–P). Merged
confocal images of diaphragm segments stained for LYVE-
1 showed an almost complete depletion of LYVE-1?
macrophages and increased lymphatic vessel branches in
Csf1r-/- pups at P7 (Fig. 5d, e). Quantification revealed
that Csf1r-/- mice had significantly increased (?51 %)
lymphatic vessel branch counts per analyzed diaphragm
segment (WT: 45.00 ± 12.02, Csf1r-/-: 68.14 ± 19.36,
n = 5–7 pups per group; p = 0.029, Fig. 5k) and a signif-
icantly increased number of lymphatic vessel loops per
analyzed diaphragm segment (?132 %; WT: 4.00 ± 1.00,
Csf1r-/-: 9.29 ± 3.45, n = 5–7 pups per group;
p = 0.006, Fig. 5l) compared to wild-type controls. The
LYVE-1? area, average branch length and vessel diameter
remained unchanged (Fig. 5m–o).
Similar results were obtained after antibody-mediated
blockade of CSF-1R. Intraperitoneal injections of AFS98, a
CSF-1R-blocking antibody, at P0, P1, P3 and P5 signifi-
cantly decreased the CD68? area in the diaphragm com-
pared to IgG control (-86 %; IgG: 0.47 ± 0.15 %,
Fig. 3 VEGFR-3 blockade leads to similar lymphatic vessel pheno-
types in the tail dermis and on the pleural diaphragm side. LYVE-1
whole mounts of tail dermis of P7 WT (a) and K14-VEGFR-3-Fc
transgenic littermates (b). LYVE-1 whole mounts of tail dermis of P5
pups treated with IgG (c) or blocking antibodies against VEGFR-1
(mF1) (d), VEGFR-2 (DC101) (e), or VEGFR-3 (mF4) (f) in utero at
E16.5 and E18.5. VEGFR-3 blockade leads in both approaches to an
almost complete inhibition of the lymphangiogenic process, whereas
VEGFR-1 and -2 blockades have no obvious effect. Scale bar 100 lm
Fig. 4 Macrophages are closely aligned with lymphatic vessels and
their sprouting tips and develop before lymphatic vessels. Diaphragm
whole mounts stained for LYVE-1 (red), CD206 (cyan) and F4/80
(green) at P8 show macrophages aligned in parallel to lymphatic
vessels (a). P7 diaphragm whole mounts show that LYVE-1 (green)-
and CD206 (cyan)-positive macrophages have close contact with the
sprouting tip of LYVE-1-positive lymphatic vessels (b, arrows), but
they are not positive for Prox-1 (red) (c). E14.5 diaphragm whole
mounts stained for CD206 (red), LYVE-1 (cyan) and CD31 (green)
show the presence of CD206- and LYVE-1-positive macrophages but
no LYVE-1-positive vessel structures (d). At E14.5, the few Prox-1?
lymphatic endothelial cells (cyan) do not co-stain for
CD68 (green) (e, arrow). Scale bars a 50 lm, b and c 50 lm,
d 100 lm, e 20 lm. (Color figure online)
Angiogenesis (2016) 19:513–524 519
123
Fig. 5 Colony-stimulating factor-1 receptor-positive macrophages
negatively regulate lymphatic vessel branching on the pleural side of
the diaphragm. P6 diaphragm whole mounts show CSF-1R and
LYVE-1 double-positive macrophages in proximity to LYVE-1-
positive lymphatic vessels (a). Compared to WT littermates (b),
CD206 (cyan)- and CD68 (red)-stained whole mounts of diaphragms
of P7 Csf1r-/- pups show depletion of macrophages (c). Segments
of pleural diaphragm LYVE-1 whole mounts of P7 WT (d) or
Csf1r-/- pups (e). CD68-stained whole mounts of IgG (f)- or AFS98
(g)-treated pups show depletion of macrophages on the pleural side of
the diaphragmatic muscle by AFS98 treatment. Quantification of the
CD68-positive area per visual field in the diaphragm (h). Dots
represent mean values per mouse, and lines indicate the group means.
Quantification of diaphragmatic lymphatic vessel development of
Csf1r-/- pups shows a significant increase in branches and
lymphatic loops compared to the WT controls (k–o). Dots represent
mean values per mouse, and lines indicate the group means. Segments
of pleural diaphragm LYVE-1 whole mounts of P7 IgG (i)- or AFS98-
treated pups (j). Quantification of diaphragmatic lymphatic vessel
development of P7 AFS98-treated pups shows a significant increase
in branches, lymphatic loops and a significant decrease in average
branch length compared to the IgG controls (p–t). Dots represent
mean values per mouse, and lines indicate the group means.
Quantifications of LEC sprouts per bead show that isolated P7
diaphragmatic macrophage-conditioned medium significantly
decreased VEGF-A/FGF-induced LEC sprouting (u). Dots represent
mean values per well, and lines indicate the group means. Scale bars
a 50 lm, b and c 50 lm, d and e 1 mm, f and g 50 lm, i and j 1 mm.
*p\ 0.05; **p\ 0.01; ***p\ 0.001. (Color figure online)
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AFS98: 0.07 ± 0.05 %, n = 5 pups per group,
p = 0.0023, Fig. 5f–h), as well as LYVE-1? macrophages
(Fig. 5i, j) at day P7. The treatment also significantly
increased the number of lymphatic vessel branches per
analyzed diaphragm segment (?40 %; IgG: 49.5 ± 12.34,
AFS98: 69.2 ± 14.55, n = 5–6 pups per group, p = 0.038,
Fig. 5p) and the loop formation by lymphatic vessels
(?200 %, IgG: 2.34 ± 1.63, AFS98: 7 ± 4.42, n = 5–6
pups per group, p = 0.039, Fig. 5q). The average lym-
phatic vessel length was significantly reduced after CSF-1R
blockade (-20 %; IgG: 219.39 ± 39.23 lm, AFS98:
174.31 ± 22.35 lm, n = 5–6 pups per group, p = 0.0495,
Fig. 5r). The LYVE-1? area and lymphatic vessel diam-
eters remained unchanged (Fig. 5s, t).
No significant differences were detectable in the LYVE-
1-positive area and the number of lymphatic vessel bran-
ches per lymphatic ring structure in the tail dermis (Sup-
plementary Material Fig. S1E–H) and the number of
lymphatic vessel branches and lymphatic valves in
mesenteric lymphatic vessels of Csf1r-/- mice (Supple-
mentary Material Fig. S1I–L).
To obtain deeper mechanistic insights into how macro-
phages might regulate lymphatic vessel branching, we next
used LEC sprouting assays [32]. We found that conditioned
media obtained from isolated P7 diaphragmatic macro-
phages significantly reduced the VEGF-A/bFGF-induced
LEC sprouting (medium ? VEGF-A/FGF: 0.671 ± 0.044
sprouts/bead; macrophage-conditioned medium ? VEGF-
A/FGF: 0.346 ± 0.021 sprouts/bead, n = 4 wells per
group, p = 0.000691, Fig. 5u). This finding indicates that
diaphragmatic macrophages inhibit LEC sprouting by
secreted factors.
Macrophage depletion does not impair lymphatic
vessel drainage function
Diaphragmatic lymphatic vessels represent a central route
for the drainage of peritoneal fluid [1, 35], draining
molecules and fluid to the mediastinal lymph nodes in adult
mice [19]. We next investigated if macrophage depletion
might also have an effect on diaphragmatic lymphatic
vessel drainage. P8 pups were injected i.p. with 10 ll of
PEGylated yellow–green fluorescent microspheres in PBS,
and the draining mediastinal lymph nodes were analyzed
after 1 h. Stereomicroscopic images showed that the
mediastinal lymph nodes contained microspheres (Fig. 6a,
arrows). Quantitative FACS analysis revealed that micro-
spheres are quantifiable in a PBS solution (Fig. 6b, c) and
that microspheres were detectable in mediastinal lymph
nodes (Fig. 6f) after i.p. injection, but not in non-draining
inguinal lymph nodes (Fig. 6e) or in mediastinal lymph
nodes of uninjected pups (Fig. 6d). After treatment with
AFS98, FACS analysis showed no significant differences
of microsphere content in the mediastinal lymph nodes, as
compared to control pups (Fig. 6g).
Discussion
Our study reveals that the submesothelial initial diaphrag-
matic lymphatic plexus of mice develops mainly after
birth. This sudden increase in lymphatic vessel growth and
branching is likely related to the gain of function of the
diaphragm with the initiation of respiration after birth. The
postnatal diaphragm provides several advantages for lym-
phatic development studies, as compared to other currently
used model organ systems for developmental lymphan-
giogenesis, including the tail dermis [39] and the mesentery
[27]. The diaphragm is easily accessible for dissection and
for intraperitoneal manipulations, and it is well suited for
whole-mount staining and imaging due to its thin and
translucent structure. Moreover, as compared to the
mesentery, it only needs a short handling time for whole-
mount staining approaches. Based on the results of our
study, combined with recent reports [14, 26], we propose
five parameters that are easily quantifiable and that allow a
detailed and reproducible evaluation of lymphatic vessel
development in the diaphragm: the average area covered by
LYVE-1? lymphatic vessels, the number of branches, the
number of vessel loops, the average branch length and the
average lymphatic vessel diameter. Further advantageous
features of the diaphragm model include the easy detection
of lymphatic vessel sprouts, allowing detailed studies of
developing lymphatic vessel tips and their interactions with
other cell types such as macrophages. This model also
allows the study of lymphatic vessel maturation processes,
due to the presence of smooth muscle cell coverage of
lymphatic vessels, the gradual downregulation of LYVE-1
expression and the formation of lymphatic valves. Impor-
tantly, lymphatic vessels in the diaphragm can also be
easily studied in adult mice whereas, e.g., whole-mount
stainings of mesenteric lymphatic vessels are not feasible
in adult mice due to fat deposition.
Our findings that the growth of lymphatic vessels on the
pleural side of the diaphragmatic muscle was almost
completely inhibited in newborn K14-VEGFR-3-Fc trans-
genic mice, where the soluble form of VEGFR-3 acts as a
decoy receptor for its ligands VEGF-C and VEGF-D, are in
line with previous reports about the postnatal inhibition of
lymphatic development in these mice [17, 22]. This effect
seems to be transient, as lymphatic vessels were reported to
be present in diaphragms of adult K14-VEGFR-3-Fc
transgenic mice [22]. The important role of the VEGF-C/
VEGF-D/VEGFR-3 signaling system was further sup-
ported by our finding that systemic treatment with the
VEGFR-3-blocking antibody mF4 potently inhibited
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diaphragmatic lymphatic vessel development, as assessed
at day 5 after birth.
In contrast to VEGFR-3, the role of VEGFR-2 in lym-
phangiogenesis has remained less well defined; however,
VEGFR-2 has previously been implicated in developmen-
tal lymphangiogenesis [34]. VEGF-C can also signal, in its
processed form, via VEGFR-2, which is expressed by
lymphatic endothelial cells [13, 38]. Our findings that
antibody-mediated VEGFR-2 blockade had no major
impact on lymphatic development in the diaphragm indi-
cate that VEGFR-2 activity is largely dispensable in this
setting. This result is in line with reports that VEGF-A, the
main ligand of VEGFR-2, cannot substitute for VEGF-C-
induced signaling in VEGF-C-deficient embryos [16].
Since a recent study found that LYVE-1-Cre-mediated
depletion of VEGFR-2 resulted in reduced lymphatic ves-
sel density in adult ear skin [7], these data indicate that the
role of VEGFR-2 in murine lymphatic vessel physiology is
organ specific and/or dependent on the developmental
stage. Our finding that blockade of VEGFR-1, which is not
expressed by lymphatic vessels and binds VEGF-A but not
VEGF-C [25], had no significant impact on lymphatic
vessel development in the diaphragm is in line with the
findings in VEGFR-1-deficient mice where the lymphatic
vessels in the ear skin were comparable to those of WT
controls [25].
Macrophages have been generally considered as
important mediators of pathological lymphangiogenesis
[11], but there are only a limited number of studies
addressing the role of macrophages during developmental
lymphangiogenesis [10, 20]. Based on our time course
analysis of pre- and postnatal development of the
diaphragmatic lymphatic vascular system, we found that
during diaphragm development, macrophages appear ear-
lier than lymphatic vessels, that they are closely associated
with the sprouting tips of the lymphatic vessels and that
they are similarly aligned as the lymphatic vessels. Thus,
we hypothesized that macrophages might have an impor-
tant influence on lymphatic development and patterning in
the diaphragm. However, quantitative morphological and
functional analyses of diaphragmatic lymphatic vessels in
postnatal Csf1r-/- mice and in mice treated with a
blocking CSF-1R antibody surprisingly did not reveal any
major abnormalities of lymphatic vessel development,
despite efficient macrophage depletion. Moreover, no sig-
nificant changes of the lymphatic drainage were detected.
Rather, macrophage depletion resulted in a subtler pheno-
type, which indicates that the major function of
Fig. 6 Macrophage depletion does not impair lymphatic vessel
drainage function. Stereomicroscope image showing fluorescent
microspheres within mediastinal lymph nodes (a, arrows) in exposed
thorax 1 h after i.p. injection of microspheres into P8 pup. T thymus,
H heart, R rib cage. FACS analysis in the FSC/SSC (b) and FITC/FSC
(c) channels. FACS analysis of green–yellow fluorescent micro-
spheres in PBS in mediastinal lymph nodes of uninjected pups (d),
and in non-draining inguinal lymph nodes (e) and in draining
mediastinal lymph nodes (f) 1 h after i.p. injection of microspheres
into WT P8 pups. Quantification by FACS showed that there was no
difference in drainage of fluorescent microspheres to pooled medi-
astinal lymph nodes 1 h after i.p. injection of microspheres into rat
IgG- or AFS98-treated P7 pups (g)
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macrophages is to modulate the patterning of lymphatic
vessels, and in this case to restrain lymphatic vessel
branching on the pleural side of the diaphragmatic muscle
by secreted factors. These effects seem to be tissue specific
since no major differences in lymphatic vessel branching
were detected in the mesentery and the tail dermis of Cs-
f1r-/- mice, whereas altered lymphatic patterning was
observed in the trachea and ear skin of postnatal mice after
CSF-1R blockade [20] and in embryonic skin and yolk sacs
of Csf1r-/- and PU.1-/- embryos [10]. PU.1-/- mice
are often used as an additional model to study the role of
macrophages during development. However, since these
mice die soon after birth [2, 24, 33], they could not be used
in the present study as the development of lymphatic ves-
sels in the diaphragm largely occurs after birth.
Based on our findings of the close localization of mac-
rophages at the lymphatic tips in the diaphragm and of the
increased lymphatic vessel branch formation in Csf1r-/-
mice and after CSF-1R antibody blockade, we hypothesize
that macrophages might act as chaperones, regulating the
branch formation of lymphatic sprouts, similar to their role
during blood vessel development in the retina [8, 29]. It
will be of great interest to further define the identity and
functional contribution of macrophage-derived signals
during developmental lymphangiogenesis in future studies.
Taken together, our results provide new information about
the time points when the submesothelial, initial diaphragmatic
lymphatic plexus develops and matures, and they identify
major molecular and cellular drivers of this process. The
developing lymphatic vessels on the pleural side of the
diaphragmatic muscle can serve as a reliable and easily quan-
tifiable in vivo model to study physiological lymphangiogen-
esis.Thismodel canalsohelp togainmoreknowledgeabout the
lymphangiogenic process and to identify and validate new
targets for anti- and pro-lymphangiogenic therapies.
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